BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989;250:607-610. [PMID: 2787758 DOI: 10.1016/0014-5793(89)80805-1] [Cited by in Crossref: 284] [Cited by in F6Publishing: 275] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Castrilli G, Tatone D, Diodoro MG, Rosini S, Piantelli M, Musiani P. Interleukin 1alpha and interleukin 6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells. Br J Cancer 1997;75:855-9. [PMID: 9062407 DOI: 10.1038/bjc.1997.152] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 1.8] [Reference Citation Analysis]
2 Tang CH, Chuang JY, Fong YC, Maa MC, Way TD, Hung CH. Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kappaB pathways and promotes osteoclastogenesis in human oral cancer cells. Carcinogenesis 2008;29:1483-92. [PMID: 18310089 DOI: 10.1093/carcin/bgn045] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
3 Brochier J, Legouffe E, Liautard J, Gaillard J, Mao L, Bataille R, Rossi J, Klein B. Immunomodulating IL-6 activity by murine monoclonal antibodies. International Journal of Immunopharmacology 1995;17:41-8. [DOI: 10.1016/0192-0561(94)00076-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Fujisawa K, Nasu K, Arima K, Sugano T, Narahara H, Miyakawa I. Production of Interleukin (IL)-6 and IL-8 by a Choriocarcinoma Cell Line, BeWo. Placenta 2000;21:354-60. [DOI: 10.1053/plac.1999.0494] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
5 Okugawa Y, Miki C, Toiyama Y, Yasuda H, Yokoe T, Saigusa S, Hiro J, Tanaka K, Inoue Y, Kusunoki M. Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer. Br J Cancer 2010;103:787-95. [PMID: 20823887 DOI: 10.1038/sj.bjc.6605827] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
6 Dosquet C, Schaetz A, Faucher C, Lepage E, Wautier JL, Richard F, Cabane J. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 1994;30A:162-7. [PMID: 8155390 DOI: 10.1016/0959-8049(94)90079-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 1.9] [Reference Citation Analysis]
7 Chung YC, Chang YF. Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol. 2003;15:369-373. [PMID: 12655256 DOI: 10.1097/00042737-200304000-00006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 2.5] [Reference Citation Analysis]
8 Yokoyama A, Maruyama M, Ito M, Kohno N, Hiwada K, Yano S. Interleukin 6 activity in pleural effusion. Its diagnostic value and thrombopoietic activity. Chest 1992;102:1055-9. [PMID: 1395742 DOI: 10.1378/chest.102.4.1055] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 1.3] [Reference Citation Analysis]
9 Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2:619-626. [PMID: 17075601 DOI: 10.1038/ncprheum0338] [Cited by in Crossref: 429] [Cited by in F6Publishing: 376] [Article Influence: 30.6] [Reference Citation Analysis]
10 Alcocer-González JM, Berumen J, Taméz-Guerra R, Bermúdez-Morales V, Peralta-Zaragoza O, Hernández-Pando R, Moreno J, Gariglio P, Madrid-Marina V. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol. 2006;19:481-491. [PMID: 16987066 DOI: 10.1089/vim.2006.19.481] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]
11 Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K, Graham DY. Relation between cytokines and Helicobacter pylori in gastric cancer. Helicobacter 2001;6:116-24. [PMID: 11422466 DOI: 10.1046/j.1523-5378.2001.00017.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 2.8] [Reference Citation Analysis]
12 Shih Y, Konrad MW, Kim Warren M, Childs A, Paradise C, Meyers FJ, Groves ES. Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolated interleukin-2. Eur J Immunol 1992;22:727-33. [DOI: 10.1002/eji.1830220316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
13 Stein B, Schrader AJ, Wegener G, Seidel C, Kuczyk MA, Steffens S. Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma. BMC Cancer 2013;13:101. [PMID: 23497335 DOI: 10.1186/1471-2407-13-101] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
14 Zurita AJ, Gagnon RC, Liu Y, Tran HT, Figlin RA, Hutson TE, D'Amelio AM Jr, Sternberg CN, Pandite LN, Heymach JV. Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma. Br J Cancer 2017;117:478-84. [PMID: 28683470 DOI: 10.1038/bjc.2017.206] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
15 Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Retroviral-mediated transfer of interleukin-6 into hematopoietic cells of mice results in a syndrome resembling Castleman's disease. Curr Top Microbiol Immunol 1990;166:37-41. [PMID: 2073814 DOI: 10.1007/978-3-642-75889-8_5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
16 Chen Y, Liu J, Lv P, Gao J, Wang M, Wang Y. IL-6 is involved in malignancy and doxorubicin sensitivity of renal carcinoma cells. Cell Adh Migr 2018;12:28-36. [PMID: 28328292 DOI: 10.1080/19336918.2017.1307482] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
17 Sawada T, Koike K, Kanda Y, Ikegami H, Jikihara H, Maeda T, Osako Y, Hirota K, Miyake A. Interleukin-6 stimulates cell proliferation of rat pituitary clonal cell lines in vitro. J Endocrinol Invest 1995;18:83-90. [DOI: 10.1007/bf03349706] [Cited by in Crossref: 25] [Cited by in F6Publishing: 2] [Article Influence: 3.6] [Reference Citation Analysis]
18 Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol. 1993;120:1281-1288. [PMID: 8436594 DOI: 10.1083/jcb.120.5.1281] [Cited by in Crossref: 159] [Cited by in F6Publishing: 157] [Article Influence: 5.7] [Reference Citation Analysis]
19 Fridman WH, Tartour E. Cytokines and cell regulation. Mol Aspects Med 1997;18:3-90. [PMID: 9100222 DOI: 10.1016/s0098-2997(96)00012-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today. 1990;11:443-449. [PMID: 2127356 DOI: 10.1016/0167-5699(90)90173-7] [Cited by in Crossref: 733] [Cited by in F6Publishing: 698] [Article Influence: 24.4] [Reference Citation Analysis]
21 Alberti L, Thomachot MC, Bachelot T, Menetrier-Caux C, Puisieux I, Blay JY. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 2004;111:653-61. [PMID: 15252833 DOI: 10.1002/ijc.20287] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
22 Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA. TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. Cytokine 2017;89:127-35. [DOI: 10.1016/j.cyto.2016.01.021] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 18.5] [Reference Citation Analysis]
23 Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, Tian E, Williams DR, Epstein J, Barlogie B, Shaughnessy JD Jr. An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood 2012;119:503-12. [PMID: 22072558 DOI: 10.1182/blood-2011-07-367052] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
24 Berek JS, Martínez-maza O. Molecular and biological factors in the pathogenesis of ovarian cancer. In: Sharp F, Mason P, Blackett T, Berek J, editors. Ovarian Cancer 3. Boston: Springer US; 1994. pp. 77-87. [DOI: 10.1007/978-1-4757-0136-4_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Nozoe T, Matsumata T, Sugimachi K. Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol. 2000;23:263-266. [PMID: 10857890 DOI: 10.1097/00000421-200006000-00011] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 3.7] [Reference Citation Analysis]
26 Mulé JJ, Marcus SG, Yang JC, Weber JS, Rosenberg SA. Clinical application of IL6 in cancer therapy. Res Immunol 1992;143:777-9. [PMID: 1439156 DOI: 10.1016/0923-2494(92)80023-e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
27 Izquierdo M, Degen D, Myers L, Levitt D, Von Hoff D. Effects of the hematopoietic growth factors GM-CSF, IL-3, and IL-6 on human tumor colony-forming units taken directly from patients. Annals of Oncology 1995;6:927-32. [DOI: 10.1093/oxfordjournals.annonc.a059361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
28 Yakirevich E, Matoso A, Sabo E, Wang LJ, Tavares R, Meitner P, Morris DJ, Pareek G, Delellis RA, Resnick MB. Expression of the glucocorticoid receptor in renal cell neoplasms: an immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study. Hum Pathol 2011;42:1684-92. [PMID: 21531004 DOI: 10.1016/j.humpath.2011.01.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
29 Zhou Y, Horiuchi S, Yamamoto M, Yamamoto N. Elevated Serum Levels of the Soluble Form of gp130, the IL-6 Signal Transducer, in HTLV-1 Infection and No Involvement of Alternative Splicing for Its Generation. Microbiology and Immunology 1998;42:109-16. [DOI: 10.1111/j.1348-0421.1998.tb02258.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
30 Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59 Suppl 1:i21-7. [PMID: 11053081 DOI: 10.1136/ard.59.suppl_1.i21] [Cited by in Crossref: 128] [Cited by in F6Publishing: 125] [Article Influence: 6.1] [Reference Citation Analysis]
31 McMillan DN, Kernohan NM, Flett ME, Heys SD, Deehan DJ, Sewell HF, Walker F, Eremin O. Interleukin 2 receptor expression and interleukin 2 localisation in human solid tumor cells in situ and in vitro: evidence for a direct role in the regulation of tumour cell proliferation. Int J Cancer 1995;60:766-72. [PMID: 7896442 DOI: 10.1002/ijc.2910600606] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]
32 de la Mata J, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR, Roodman GD. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995;95:2846-52. [PMID: 7769125 DOI: 10.1172/JCI117990] [Cited by in Crossref: 170] [Cited by in F6Publishing: 43] [Article Influence: 6.5] [Reference Citation Analysis]
33 Chen R, Du X, Cui Y, Zhang X, Ge Q, Dong J, Zhao X. Vertical Flow Assay for Inflammatory Biomarkers Based on Nanofluidic Channel Array and SERS Nanotags. Small 2020;16:e2002801. [PMID: 32567225 DOI: 10.1002/smll.202002801] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
34 Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, Kurogi J, Tajiri N, Inoue K, Niizeki T. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007;27:1091-1097. [PMID: 17845537 DOI: 10.1111/j.1478-3231.2007.01550.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 4.5] [Reference Citation Analysis]
35 Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71:354-356. [PMID: 7841052 DOI: 10.1038/bjc.1995.71] [Cited by in Crossref: 140] [Cited by in F6Publishing: 128] [Article Influence: 5.4] [Reference Citation Analysis]
36 Tzeng HE, Tsai CH, Chang ZL, Su CM, Wang SW, Hwang WL, Tang CH. Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma. Biochem Pharmacol. 2013;85:531-540. [PMID: 23219526 DOI: 10.1016/j.bcp.2012.11.021] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 8.2] [Reference Citation Analysis]
37 Miki C, Konishi N, Ojima E, Hatada T, Inoue Y, Kusunoki M. C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci. 2004;49:970-976. [PMID: 15309885 DOI: 10.1023/B: DDAS.0000034556.48527.6e] [Reference Citation Analysis]
38 Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, Chen M, Albino AP, Bander NH. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993;55:96-101. [PMID: 8344757 DOI: 10.1002/ijc.2910550118] [Cited by in Crossref: 177] [Cited by in F6Publishing: 165] [Article Influence: 6.3] [Reference Citation Analysis]
39 Blay J, Rossi J, Wijdenes J, Menetrier-caux C, Schemann S, Négrier S, Philip T, Favrot M. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997;72:424-30. [DOI: 10.1002/(sici)1097-0215(19970729)72:3<424::aid-ijc9>3.0.co;2-r] [Cited by in Crossref: 166] [Cited by in F6Publishing: 39] [Article Influence: 6.9] [Reference Citation Analysis]
40 Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martínez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991;164:1038-1042; discussion 1042-1043;. [PMID: 2014824 DOI: 10.1016/0002-9378(91)90582-c] [Cited by in Crossref: 149] [Cited by in F6Publishing: 51] [Article Influence: 5.0] [Reference Citation Analysis]
41 Takenawa J, Kaneko Y, Okumura K, Yoshida O, Nakayama H, Fujita J. Investigative Urology: Inhibitory Effect of Dexamethasone and Progesterone in Vitro on Proliferation of Human Renal Cell Carcinomas and Effects on Expression of Interleukin-6 or Interleukin-6 Receptor. The Journal of Urology. [DOI: 10.1097/00005392-199503000-00088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Ishihara H, Kondo T, Omae K, Takagi T, Iizuka J, Kobayashi H, Tanabe K. Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment. Targ Oncol 2016;11:605-17. [DOI: 10.1007/s11523-016-0430-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
43 Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today. 1997;18:493-497. [PMID: 9357142 DOI: 10.1016/s0167-5699(97)01115-8] [Cited by in Crossref: 269] [Cited by in F6Publishing: 35] [Article Influence: 11.7] [Reference Citation Analysis]
44 Stouthard JM, Goey H, de Vries EG, de Mulder PH, Groenewegen A, Pronk L, Stoter G, Sauerwein HP, Bakker PJ, Veenhof CH. Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial. Br J Cancer 1996;73:789-93. [PMID: 8611381 DOI: 10.1038/bjc.1996.137] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
45 Berek JS, Martínez-Maza O, Hamilton T, Tropé C, Kaern J, Baak J, Rustin GJ. Molecular and biological factors in the pathogenesis of ovarian cancer. Ann Oncol 1993;4 Suppl 4:3-16. [PMID: 8312207 DOI: 10.1093/annonc/4.suppl_4.s3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'alessandro N. Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 1999;85:134-44. [DOI: 10.1002/(sici)1097-0142(19990101)85:1<134::aid-cncr19>3.0.co;2-c] [Cited by in Crossref: 55] [Article Influence: 2.5] [Reference Citation Analysis]
47 Ohi S, Hashimoto H, Tachibana T, Tabei I, Nakajima M, Sato K, Yanaga K, Ishikawa H. Establishment and characterization of EB virus-free normal B-lymphocyte and interleukin-6-producing poorly differentiated adenocarcinoma cell lines derived from gastric tumor tissue. Hum Cell 2005;18:35-44. [PMID: 16130898 DOI: 10.1111/j.1749-0774.2005.tb00055.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
48 Armstrong CA, Murray N, Kennedy M, Koppula SV, Tara D, Ansel JC. Melanoma-Derived Interleukin 6 Inhibits In Vivo Melanoma Growth. Journal of Investigative Dermatology 1994;102:278-84. [DOI: 10.1111/1523-1747.ep12371782] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
49 Taide M, Kanda S, Eguchi J, Igawa T, Kanetake H, Saito Y. A study of growth factors in human renal cysts with or without renal cell carcinoma. Clin Chim Acta 1993;217:199-203. [PMID: 8261629 DOI: 10.1016/0009-8981(93)90166-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
50 Chuang JY, Huang YL, Yen WL, Chiang IP, Tsai MH, Tang CH. Syk/JNK/AP-1 signaling pathway mediates interleukin-6-promoted cell migration in oral squamous cell carcinoma. Int J Mol Sci 2014;15:545-59. [PMID: 24398980 DOI: 10.3390/ijms15010545] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
51 Bauknecht T, Randelzhofer B, Schmitt B, Ban Z, Hernando JJ. Response to IL-6 of HPV-18 cervical carcinoma cell lines. Virology 1999;258:344-54. [PMID: 10366571 DOI: 10.1006/viro.1999.9722] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
52 Srivani R, Nagarajan B. A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer 2003;13:331-9. [DOI: 10.1046/j.1525-1438.2003.13197.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
53 Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F, Joyeux I, Pouillart P, Fridman WH. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994;69:911-3. [PMID: 8180022 DOI: 10.1038/bjc.1994.175] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 3.2] [Reference Citation Analysis]
54 Gruss H, Brach MA, Mertelsmann RH, Herrmann F. Interferon-gamma interrupts autocrine growth mediated by endogenous interleukin-6 in renal-cell carcinoma. Int J Cancer 1991;49:770-3. [DOI: 10.1002/ijc.2910490523] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
55 Todo T, Adams EF, Rafferty B, Fahlbusch R, Dingermann T, Werner H. Secretion of interleukin-6 by human meningioma cells: possible autocrine inhibitory regulation of neoplastic cell growth. Journal of Neurosurgery 1994;81:394-401. [DOI: 10.3171/jns.1994.81.3.0394] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.1] [Reference Citation Analysis]
56 Maeurer MJ, Martin DM, Castelli C, Elder E, Leder G, Storkus WJ, Lotze MT. Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 1995;41:111-21. [DOI: 10.1007/bf01527407] [Cited by in Crossref: 51] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
57 Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R, Kishimoto T, Nakatani T. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer. 2002;86:1396-1400. [PMID: 11986770 DOI: 10.1038/sj.bjc.6600257] [Cited by in Crossref: 111] [Cited by in F6Publishing: 95] [Article Influence: 5.8] [Reference Citation Analysis]
58 Hrab M, Olek-Hrab K, Antczak A, Kwias Z, Milecki T. Interleukin-6 (IL-6) and C-reactive protein (CRP) concentration prior to total nephrectomy are prognostic factors in localized renal cell carcinoma (RCC). Rep Pract Oncol Radiother 2013;18:304-9. [PMID: 24416568 DOI: 10.1016/j.rpor.2013.06.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
59 Kobayashi T, Honke K, Gasa S, Kato N, Miyazaki T, Makita A. Epidermal growth factor elevates the activity levels of glycolipid sulfotransferases in renal-cell-carcinoma cells. Int J Cancer. 1993;55:448-452. [PMID: 8104164 DOI: 10.1002/ijc.2910550321] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
60 Miki S, Tsukada S, Nakamura Y, Aimoto S, Hojo H, Sato B, Yamamoto M, Miki Y. Functional and possible physical association of scavenger receptor with cytoplasmic tyrosine kinase Lyn in monocytic THP-1-derived macrophages. FEBS Lett 1996;399:241-4. [PMID: 8985154 DOI: 10.1016/s0014-5793(96)01332-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
61 Oka M, Iizuka N, Yamamoto K, Gondo T, Abe T, Hazama S, Akitomi Y, Koishihara Y, Ohsugi Y, Ooba Y, Ishihara T, Suzuki T. The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996;16:1001-6. [PMID: 8974001 DOI: 10.1089/jir.1996.16.1001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.3] [Reference Citation Analysis]
62 Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998;176:335-338. [PMID: 9817250 DOI: 10.1016/s0002-9610(98)00204-9] [Cited by in Crossref: 158] [Cited by in F6Publishing: 65] [Article Influence: 6.9] [Reference Citation Analysis]
63 Chonov DC, Ignatova MMK, Ananiev JR, Gulubova MV. IL-6 Activities in the Tumour Microenvironment. Part 1. Open Access Maced J Med Sci 2019;7:2391-8. [PMID: 31592285 DOI: 10.3889/oamjms.2019.589] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
64 Papac RJ, Poo-hwu W. Renal Cell Carcinoma: A Paradigm of Lanthanic Disease. American Journal of Clinical Oncology 1999;22:223-31. [DOI: 10.1097/00000421-199906000-00003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
65 Hess S, Smola H, Sandaradura de Silva U, Hadaschik D, Kube D, Baldus SE, Flucke U, Pfister H. Loss of IL-6 Receptor Expression in Cervical Carcinoma Cells Inhibits Autocrine IL-6 Stimulation: Abrogation of Constitutive Monocyte Chemoattractant Protein-1 Production. J Immunol 2000;165:1939-48. [DOI: 10.4049/jimmunol.165.4.1939] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
66 Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994;73:1882-8. [PMID: 8137215 DOI: 10.1002/1097-0142(19940401)73:7<1882::aid-cncr2820730718>3.0.co;2-r] [Cited by in Crossref: 114] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
67 Li YY, Hsieh LL, Tang RP, Liao SK, Yeh KY. Interleukin-6 (IL-6) released by macrophages induces IL-6 secretion in the human colon cancer HT-29 cell line. Hum Immunol. 2009;70:151-158. [PMID: 19272324 DOI: 10.1016/j.humimm.2009.01.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
68 Kurzrock R, Estrov Z, Ku S, Leonard M, Talpaz M. Interleukin-1 increases expression of the LYT-10 (NFκB2) proto-oncogene/transcription factor in renal cell carcinoma lines. Journal of Laboratory and Clinical Medicine 1998;131:261-8. [DOI: 10.1016/s0022-2143(98)90099-3] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
69 Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer. 2007;110:1911-1928. [PMID: 17849470 DOI: 10.1002/cncr.22999] [Cited by in Crossref: 270] [Cited by in F6Publishing: 243] [Article Influence: 19.3] [Reference Citation Analysis]
70 Costes V, Liautard J, Picot MC, Robert M, Lequeux N, Brochier J, Baldet P, Rossi JF. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J Clin Pathol 1997;50:835-40. [PMID: 9462266 DOI: 10.1136/jcp.50.10.835] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
71 Kallen KJ, zum Büschenfelde KH, Rose-John S. The therapeutic potential of interleukin-6 hyperagonists and antagonists. Expert Opin Investig Drugs 1997;6:237-66. [PMID: 15989626 DOI: 10.1517/13543784.6.3.237] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
72 Tsukamoto T, Kumamoto Y, Miyao N, Masumori N, Takahashi A, Yanase M. Interleukin-6 in renal cell carcinoma. J Urol 1992;148:1778-81; discussion 1781-2. [PMID: 1433606 DOI: 10.1016/s0022-5347(17)37026-x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
73 Uehara T, Yano T, Kuninaka S, Yoshino I, Asoh H, Ichinose Y. The influence of enhanced postoperative inflammation by the intrapleural administration of streptococcal preparation (OK-432) on the prognosis of completely resected non-small-cell lung cancer. J Surg Oncol 2000;75:51-4. [PMID: 11025462 DOI: 10.1002/1096-9098(200009)75:1<51::aid-jso9>3.0.co;2-f] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
74 Oka M, Hirose K, Iizuka N, Aoyagi K, Yamamoto K, Abe T, Hazama S, Suzuki T. Cytokine mRNA expression patterns in human esophageal cancer cell lines. J Interferon Cytokine Res 1995;15:1005-9. [PMID: 8590302 DOI: 10.1089/jir.1995.15.1005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 1.6] [Reference Citation Analysis]
75 Okamoto M, Hattori K, Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell linesin vitro. Int J Cancer 1997;72:149-54. [DOI: 10.1002/(sici)1097-0215(19970703)72:1<149::aid-ijc21>3.0.co;2-d] [Cited by in Crossref: 71] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
76 Tang CH, Chen CF, Chen WM, Fong YC. IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells. J Biol Chem 2011;286:11056-66. [PMID: 21278254 DOI: 10.1074/jbc.M110.204081] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
77 Hwang IR, Hsu PI, Peterson LE, Gutierrez O, Kim JG, Graham DY, Yamaoka Y. Interleukin-6 genetic polymorphisms are not related to Helicobacter pylori-associated gastroduodenal diseases. Helicobacter. 2003;8:142-148. [PMID: 12662382 DOI: 10.1046/j.1523-5378.2003.00135.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
78 Fujita T, Tabata KI, Ishii D, Matsumoto K, Yoshida K, Iwamura M. Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib. Mol Clin Oncol 2017;6:691-6. [PMID: 28529744 DOI: 10.3892/mco.2017.1201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
79 Yanagawa H, Sone S, Munekata M, Atagi S, Nii A, Ogura T. IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2. Clin Exp Immunol 1992;88:207-12. [PMID: 1315227 DOI: 10.1111/j.1365-2249.1992.tb03063.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
80 Kedar I, Mermershtain W, Ivgi H. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int J Cancer 2004;110:260-5. [PMID: 15069691 DOI: 10.1002/ijc.20089] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
81 Rubbert-Roth A, Sebba A, Brockwell L, Kelman A, Porter-Brown B, Pulley J, Napalkov P, van Vollenhoven RF. Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab. RMD Open 2016;2:e000213. [PMID: 27252893 DOI: 10.1136/rmdopen-2015-000213] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
82 Lewko WM, Oldham RK. Cytokines. In: Oldham RK, Dillman RO, editors. Principles of Cancer Biotherapy. Dordrecht: Springer Netherlands; 2009. pp. 155-276. [DOI: 10.1007/978-90-481-2289-9_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
83 Buyalos RP, Watson JM, Martinez-maza O. Detection of interleukin-6 in human follicular fluid**Presented at the 46th Annual Meeting of The American Fertility Society, Washington, D.C., October 15 to 18, 1990.††Supported by a grant from the California Institute for Cancer Research, Los Angeles, California, and by grants CA 01588 from the National Institutes of Health and CA 09120 from the National Institutes of Health Tumor Immunology Institutional Training, Bethesda, Maryland. Fertility and Sterility 1992;57:1230-4. [DOI: 10.1016/s0015-0282(16)55079-1] [Cited by in Crossref: 39] [Article Influence: 1.3] [Reference Citation Analysis]
84 Horiguchi A, Oya M, Marumo K, Murai M. STAT3, but not ERKs, mediates the IL-6–induced proliferation of renal cancer cells, ACHN and 769P. Kidney International 2002;61:926-38. [DOI: 10.1046/j.1523-1755.2002.00206.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 3.2] [Reference Citation Analysis]
85 Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH, Rubin SC. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 1993;83:433-41. [DOI: 10.1111/j.1365-2141.1993.tb04668.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 2.3] [Reference Citation Analysis]
86 Kobayashi T, Honke K, Gasa S, Miyazaki T, Tajima H, Matsumoto K, Nakamura T, Makita A. Hepatocyte growth factor elevates the activity levels fo glycolipid sulfotransferases in renal cell carcinoma cells. Eur J Biochem 1994;219:407-13. [DOI: 10.1111/j.1432-1033.1994.tb19953.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
87 Kaelin WG. Molecular Biology of Kidney Cancer. In: Lara PN, Jonasch E, editors. Kidney Cancer. Cham: Springer International Publishing; 2015. pp. 31-57. [DOI: 10.1007/978-3-319-17903-2_3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
88 Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, King KL, Loong CC, Hsia CY, Chi CW. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg. 2000;231:552-558. [PMID: 10749617 DOI: 10.1097/00000658-200004000-00015] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 4.5] [Reference Citation Analysis]
89 Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation of Signal Transducer and Activator of Transcription 3 in Renal Cell Carcinoma: A Study of Incidence and Its Association With Pathological Features and Clinical Outcome. Journal of Urology 2002;168:762-5. [DOI: 10.1016/s0022-5347(05)64741-6] [Cited by in Crossref: 116] [Article Influence: 6.1] [Reference Citation Analysis]
90 Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002;277:7076-85. [PMID: 11751884 DOI: 10.1074/jbc.M108255200] [Cited by in Crossref: 250] [Cited by in F6Publishing: 108] [Article Influence: 12.5] [Reference Citation Analysis]
91 Cervello M, Notarbartolo M, Landino M, Cusimano A, Virruso L, Montalto G, D'alessandro N. Downregulation of wild-type β-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effects of the cytokine? European Journal of Cancer 2001;37:512-9. [DOI: 10.1016/s0959-8049(00)00421-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
92 Dowdall JF, Winter DC, Andrews E, Laug WE, Wang JH, Redmond HP. Soluble interleukin 6 receptor (sIL-6R) mediates colonic tumor cell adherence to the vascular endothelium: a mechanism for metastatic initiation? J Surg Res 2002;107:1-6. [PMID: 12384057 DOI: 10.1006/jsre.2001.6222] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
93 Ahirwar DK, Manchanda PK, Mittal RD, Bid HK. BCG response prediction with cytokine gene variants and bladder cancer: where we are? J Cancer Res Clin Oncol 2011;137:1729-38. [PMID: 21932129 DOI: 10.1007/s00432-011-1056-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
94 Miki C, Konishi N, Ojima E, Hatada T, Inoue Y, Kusunoki M. C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci. 2004;49:970-976. [PMID: 15309885 DOI: 10.1023/b:ddas.0000034556.48527.6e] [Cited by in Crossref: 79] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
95 Nishimura N, Kanda S, Yogi Y, Kawamura M, Nakamura M, Hyakutake H, Kanetake H, Saito Y. Secretion of autocrine growth-promoting activity by renal-carcinoma cells treated with 5-fluorouracil. Int J Cancer 1992;52:105-9. [DOI: 10.1002/ijc.2910520119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
96 Li L, Kaelin WG Jr. New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am 2011;25:667-86. [PMID: 21763962 DOI: 10.1016/j.hoc.2011.04.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
97 Simpson WG, Heys SD, Whiting PH, Eremin O, Broom J. Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer. Clin Exp Immunol 1995;99:143-7. [PMID: 7531626 DOI: 10.1111/j.1365-2249.1995.tb05524.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
98 Saito K, Kihara K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol 2013;20:161-71. [PMID: 22897628 DOI: 10.1111/j.1442-2042.2012.03121.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
99 Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol. 2006;12:2563-2568. [PMID: 16688802 DOI: 10.3748/wjg.v12.i16] [Reference Citation Analysis]
100 Yasuda Y, Saito K, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 2013;18:884-9. [DOI: 10.1007/s10147-012-0454-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
101 Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000;58:647-657. [PMID: 10916088 DOI: 10.1046/j.1523-1755.2000.00211.x] [Cited by in Crossref: 160] [Cited by in F6Publishing: 123] [Article Influence: 7.6] [Reference Citation Analysis]
102 Ito Y, Fukatsu A, Baba M, Mizuno M, Ichida S, Sado Y, Matsuo S. Pathogenic significance of interleukin-6 in a patient with antiglomerular basement membrane antibody-induced glomerulonephritis with multinucleated giant cells. Am J Kidney Dis 1995;26:72-9. [PMID: 7611272 DOI: 10.1016/0272-6386(95)90157-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
103 Legouffe E, Liautard J, Gaillard JP, Rossi JF, Wijdenes J, Bataille R, Klein B, Brochier J. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immunol 1994;98:323-9. [PMID: 7955540 DOI: 10.1111/j.1365-2249.1994.tb06145.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
104 Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, Mccabe C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N, Mckane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D. Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Programme Grants Appl Res 2018;6:1-528. [DOI: 10.3310/pgfar06030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
105 Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in Immunology. 2014;26:54-74. [PMID: 24552665 DOI: 10.1016/j.smim.2014.01.001] [Cited by in Crossref: 319] [Cited by in F6Publishing: 274] [Article Influence: 45.6] [Reference Citation Analysis]
106 Cho D, Kang H, Ma J, Kim S, Kim H, Pyun K, Choi I. IL-6 undergoes transition from in vitro autocrine growth factor to in vivo growth inhibitor of B lymphoma cells. J Biomed Sci 1997;4:201-7. [DOI: 10.1007/bf02253419] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
107 Hernández-quintero M, Kuri-harcuch W, González Robles A, Castro-muñozledo F. Interleukin-6 promotes human epidermal keratinocyte proliferation and keratin cytoskeleton reorganization in culture. Cell Tissue Res 2006;325:77-90. [DOI: 10.1007/s00441-006-0173-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
108 Cho DS, Kim SJ, Lee SH, Ahn HS, Kim YS, Kim SI. Prognostic significance of preoperative C-reactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma. Korean J Urol 2011;52:104-9. [PMID: 21379426 DOI: 10.4111/kju.2011.52.2.104] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
109 Inoue M, Miki C, Okita Y, Otake K, Yoshiyama S, Uchida K, Kusunoki M. Naturally acquired regulatory mechanism of perioperative cytokine response in neonates. Pediatr Surg Int 2007;23:249-55. [DOI: 10.1007/s00383-006-1824-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41:2502-2512. [PMID: 16199153 DOI: 10.1016/j.ejca.2005.08.016] [Cited by in Crossref: 608] [Cited by in F6Publishing: 570] [Article Influence: 38.0] [Reference Citation Analysis]
111 Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol. 1994;9:462-467. [PMID: 7827297 DOI: 10.1111/j.1440-1746.1994.tb01275.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 2.5] [Reference Citation Analysis]
112 Paule B, Belot J, Rudant C, Coulombel C, Abbou CC. The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study. J Clin Pathol. 2000;53:388-390. [PMID: 10889822 DOI: 10.1136/jcp.53.5.388] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
113 Gaillard JP, Liautard J, Mani JC, Fernandez Suarez JM, Klein B, Brochier J. Identification of a novel antigenic structure of the human receptor for interleukin-6 involved in the interaction with the glycoprotein 130 chain. Immunology 1996;89:135-41. [PMID: 8911151 DOI: 10.1046/j.1365-2567.1996.d01-709.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
114 Miki S, Yamada H, Orita T, Yamamoto M, Miki Y. Suicide process of renal cell carcinoma cells encountering mumps virus. FEBS Lett 1991;278:179-82. [PMID: 1991509 DOI: 10.1016/0014-5793(91)80111-f] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
115 Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K. Prognostic Impact of Postoperative C-Reactive Protein Level in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy. Journal of Urology 2008;180:515-9. [DOI: 10.1016/j.juro.2008.04.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
116 Bihl M, Tamm M, Nauck M, Wieland H, Perruchoud AP, Roth M. Proliferation of Human Non–Small-Cell Lung Cancer Cell Lines: Role of Interleukin-6. Am J Respir Cell Mol Biol 1998;19:606-12. [DOI: 10.1165/ajrcmb.19.4.3247] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 1.7] [Reference Citation Analysis]
117 Meffert M, Hanninen EL, Menzel T, Schomburg A, Duensing S, Dallmann I, Grosse J, Vocke S, Buer J, Deckert M. In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2. Cancer Biother 1994;9:307-16. [PMID: 7719378 DOI: 10.1089/cbr.1994.9.307] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
118 Miki C, Tonouchi H, Wakuda R, Hatada T, Inoue Y, Minato E, Kobayashi M, Kusunoki M. Intra-tumoral interleukin-6 down-regulation system and genetic mutations of tumor suppressor genes in colorectal carcinoma. Cancer 2002;94:1584-92. [PMID: 11920517 DOI: 10.1002/cncr.10324] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
119 Brach MA, Herrmann F. Interleukin 6: presence and future. Int J Clin Lab Res 1992;22:143-51. [DOI: 10.1007/bf02591414] [Cited by in Crossref: 32] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
120 Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997;33:1794-8. [PMID: 9470835 DOI: 10.1016/s0959-8049(97)00179-2] [Cited by in Crossref: 69] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
121 Kamińska K, Czarnecka AM, Escudier B, Lian F, Szczylik C. Interleukin-6 as an emerging regulator of renal cell cancer. Urol Oncol 2015;33:476-85. [PMID: 26296264 DOI: 10.1016/j.urolonc.2015.07.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
122 Adams EF, Rafferty B, Mower J, Ward H, Petersen B, Fahlbusch R. Human Acoustic Neuromas Secrete Interleukin-6 in Cell Culture. Neurosurgery 1994;35:434-8. [DOI: 10.1227/00006123-199409000-00011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
123 Chudek J, Schullerus D, Wilhelm M, Kovacs G. Lack of interleukin 6 (IL-6) and transforming growth factor alpha (TGF-alpha) expression in chromophobe renal cell carcinomas. Br J Cancer 1998;78:1162-4. [PMID: 9820173 DOI: 10.1038/bjc.1998.647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
124 Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992;62:S60-5. [PMID: 1728989 DOI: 10.1016/0090-1229(92)90042-m] [Cited by in Crossref: 141] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
125 Zhang HH, Kuang S, Wang Y, Sun XX, Gu Y, Hu LH, Yu Q. Bigelovin inhibits STAT3 signaling by inactivating JAK2 and induces apoptosis in human cancer cells. Acta Pharmacol Sin 2015;36:507-16. [PMID: 25619393 DOI: 10.1038/aps.2014.143] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
126 Yasuda Y, Saito K, Yuasa T, Uehara S, Kawamura N, Yokoyama M, Ishioka J, Matsuoka Y, Yamamoto S, Okuno T, Yonese J, Kihara K, Fujii Y. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 2017;22:1081-6. [PMID: 28733795 DOI: 10.1007/s10147-017-1166-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
127 Lu C, Vickers MF, Kerbel RS. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci U S A 1992;89:9215-9. [PMID: 1409627 DOI: 10.1073/pnas.89.19.9215] [Cited by in Crossref: 104] [Cited by in F6Publishing: 97] [Article Influence: 3.6] [Reference Citation Analysis]
128 Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990;86:592-9. [PMID: 2384605 DOI: 10.1172/JCI114749] [Cited by in Crossref: 220] [Cited by in F6Publishing: 70] [Article Influence: 7.1] [Reference Citation Analysis]
129 Falkensammer CE, Thurnher M, Leonhartsberger N, Ramoner R. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival. BJU Int 2011;107:1893-8. [PMID: 21070572 DOI: 10.1111/j.1464-410X.2010.09817.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
130 Rezai AR, Rezai A, Mart�nez-maza O, Vander-meyden M, Weiss MH. Interleukin-6 and interleukin-6 receptor gene expression in pituitary tumors. J Neuro-Oncol 1994;19:131-5. [DOI: 10.1007/bf01306454] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
131 Kurebayashi J. Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications. Breast Cancer 2000;7:124-9. [PMID: 11029783 DOI: 10.1007/BF02967443] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
132 Weissglas MG, Schamhart DHJ, Löwik CWGM, Papapoulos SE, Theuns HM, Kurth K. The Role of Interleukin-6 in the Induction of Hypercalcemia in Renal Cell Carcinoma Transplanted into Nude Mice. Endocrinology 1997;138:1879-85. [DOI: 10.1210/endo.138.5.5095] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
133 Vanderschueren B, Dumon JC, Oleffe V, Heymans C, G�rain J, Body JJ. Circulating concentrations of interleukin-6 in cancer patients and their pathogenic role in tumor-induced hypercalcemia. Cancer Immunol Immunother 1994;39:286-90. [DOI: 10.1007/bf01519980] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
134 Labbozzetta M, Notarbartolo M, Poma P, Giannitrapani L, Cervello M, Montalto G, D’Alessandro N. Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma. Ann N Y Acad Sci. 2006;1089:268-275. [PMID: 17261774 DOI: 10.1196/annals.1386.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
135 Wei LH, Kuo ML, Chen CA, Chou CH, Cheng WF, Chang MC, Su JL, Hsieh CY. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene 2001;20:5799-809. [PMID: 11593385 DOI: 10.1038/sj.onc.1204733] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 5.2] [Reference Citation Analysis]
136 Ginzburg S, Golovine KV, Makhov PB, Uzzo RG, Kutikov A, Kolenko VM. Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate 2014;74:177-86. [PMID: 24151226 DOI: 10.1002/pros.22739] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
137 Okamoto M, Webber MM, Quader S, Oyasu R. Interleukin-6 and epidermal growth factor promote anchorage-independent growth of immortalized human prostatic epithelial cells treated withN-methyl-N-nitrosourea. Prostate 1998;35:255-62. [DOI: 10.1002/(sici)1097-0045(19980601)35:4<255::aid-pros4>3.0.co;2-f] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Ito R, Yasui W, Kuniyasu H, Yokozaki H, Tahara E. Expression of interleukin-6 and its effect on the cell growth of gastric carcinoma cell lines. Jpn J Cancer Res. 1997;88:953-958. [PMID: 9414656 DOI: 10.1111/j.1349-7006.1997.tb00314.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
139 Hirano T, Matsuda T, Nakajima K. Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily. Stem Cells 1994;12:262-77. [PMID: 8075593 DOI: 10.1002/stem.5530120303] [Cited by in Crossref: 125] [Cited by in F6Publishing: 110] [Article Influence: 4.6] [Reference Citation Analysis]
140 Jun CH, Ki HS, Lee KH, Park KJ, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK. Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE. Clin Mol Hepatol. 2013;19:70-77. [PMID: 23593612 DOI: 10.3350/cmh.2013.19.1.70] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
141 Thies A, Nugel D, Pfüller U, Moll I, Schumacher U. Influence of mistletoe lectins and cytokines induced by them on cell proliferation of human melanoma cells in vitro. Toxicology 2005;207:105-16. [PMID: 15590126 DOI: 10.1016/j.tox.2004.09.009] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
142 Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006;12:2563-8. [PMID: 16688802 DOI: 10.3748/wjg.v12.i16.2563] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 67] [Article Influence: 4.3] [Reference Citation Analysis]
143 Stadler W, Vogelzang NJ. Human renal cancer carcinogenesis: a review of recent advances. Ann Oncol 1993;4:451-62. [PMID: 8394735 DOI: 10.1093/oxfordjournals.annonc.a058550] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.6] [Reference Citation Analysis]
144 Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard JY, Chevreau C, Lasset C, Blay JY. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d’Immunotherapie. J Clin Oncol. 2004;22:2371-2378. [PMID: 15197198 DOI: 10.1200/jco.2004.06.121] [Cited by in Crossref: 131] [Cited by in F6Publishing: 39] [Article Influence: 7.7] [Reference Citation Analysis]
145 Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122:143-159. [PMID: 22029668 DOI: 10.1042/cs20110340] [Cited by in Crossref: 391] [Cited by in F6Publishing: 212] [Article Influence: 39.1] [Reference Citation Analysis]
146 Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev. 2013;39:89-96. [PMID: 22858249 DOI: 10.1016/j.ctrv.2012.07.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
147 Moran DM, Mattocks MA, Cahill PA, Koniaris LG, McKillop IH. Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. J Surg Res 2008;147:23-33. [PMID: 17574577 DOI: 10.1016/j.jss.2007.04.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
148 Omae K, Kondo T, Kennoki T, Takagi T, Iizuka J, Kobayashi H, Hashimoto Y, Tanabe K. Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. Int J Clin Oncol 2016;21:126-32. [PMID: 26163345 DOI: 10.1007/s10147-015-0871-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
149 Yeh KY, Li YY, Hsieh LL, Chen JR, Tang RP. The -174 G/C polymorphism in interleukin-6 (IL-6) promoter region is associated with serum IL-6 and carcinoembryonic antigen levels in patients with colorectal cancers in Taiwan. J Clin Immunol 2010;30:53-9. [PMID: 19728052 DOI: 10.1007/s10875-009-9324-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
150 Moran DM, Mayes N, Koniaris LG, Cahill PA, McKillop IH. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma. Liver Int. 2005;25:445-457. [PMID: 15780071 DOI: 10.1111/j.1478-3231.2005.01083.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
151 Adler G, Eichman W, Szczepanski M, Targonska I, Jasinska A. Postoperative Plasma Interleukin-6 in Patients with Renal Cancer Correlates with C-reactive Protein but Not with Total Fibrinogen or with High Molecular Weight Fibrinogen Fraction. Thrombosis Research 1998;89:243-8. [DOI: 10.1016/s0049-3848(98)00011-5] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
152 Weber K, Doucet M, Kominsky S. Renal cell carcinoma bone metastasis--elucidating the molecular targets. Cancer Metastasis Rev 2007;26:691-704. [PMID: 17768599 DOI: 10.1007/s10555-007-9090-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
153 Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 2000;42:1-7. [DOI: 10.1002/(sici)1097-0045(20000101)42:1<1::aid-pros1>3.0.co;2-y] [Cited by in Crossref: 71] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
154 Moretti S, Chiarugi A, Semplici F, Salvi A, De Giorgi V, Fabbri P, Mazzoli S. Serum imbalance of cytokines in melanoma patients. Melanoma Res 2001;11:395-9. [PMID: 11479428 DOI: 10.1097/00008390-200108000-00010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
155 Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1-78. [PMID: 8379461 DOI: 10.1016/s0065-2776(08)60532-5] [Cited by in Crossref: 903] [Cited by in F6Publishing: 234] [Article Influence: 32.3] [Reference Citation Analysis]
156 Horiguchi A, Oya M, Uchida A, Marumo K, Murai M. Elevated Akt Activation and Its Impact on Clinicopathological Features of Renal Cell Carcinoma. Journal of Urology 2003;169:710-3. [DOI: 10.1016/s0022-5347(05)63998-5] [Cited by in Crossref: 67] [Article Influence: 3.7] [Reference Citation Analysis]
157 Hao W, Zhu Y, Zhou H. Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer. Med Oncol 2013;30:333. [PMID: 23269580 DOI: 10.1007/s12032-012-0333-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
158 Zwierzina H. Practical aspects of cytokine therapy: Practical Aspects of Cytokine Therapy. STEM CELLS 1993;11:144-53. [DOI: 10.1002/stem.5530110301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
159 Wu Z, Yang W, Liu J, Zhang F. Interleukin-6 upregulates SOX18 expression in osteosarcoma. Onco Targets Ther 2017;10:5329-36. [PMID: 29184419 DOI: 10.2147/OTT.S149905] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Saito K, Kihara K. Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Rev Anticancer Ther 2010;10:1979-89. [PMID: 21110763 DOI: 10.1586/era.10.192] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
161 Nishimoto N, Ito A, Ono M, Tagoh H, Matsumoto T, Tomita T, Ochi T, Yoshizaki K. IL-6 inhibits the proliferation of fibroblastic synovial cells from rheumatoid arthritis patients in the presence of soluble IL-6 receptor. Int Immunol 2000;12:187-93. [PMID: 10653854 DOI: 10.1093/intimm/12.2.187] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 1.7] [Reference Citation Analysis]
162 Kuninaka S, Yano T, Yokoyama H, Fukuyama Y, Terazaki Y, Uehara T, Kanematsu T, Asoh H, Ichinose Y. DIRECT INFLUENCES OF PRO-INFLAMMATORY CYTOKINES (IL-1β, TNF-α, IL-6) ON THE PROLIFERATION AND CELL-SURFACE ANTIGEN EXPRESSION OF CANCER CELLS. Cytokine 2000;12:8-11. [DOI: 10.1006/cyto.1998.0504] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
163 Sootichote R, Thuwajit P, Singsuksawat E, Warnnissorn M, Yenchitsomanus PT, Ithimakin S, Chantharasamee J, Thuwajit C. Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8. BMC Cancer 2018;18:231. [PMID: 29486738 DOI: 10.1186/s12885-018-4155-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
164 Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000;86:203-207. [PMID: 10930915 DOI: 10.1046/j.1464-410x.2000.00792.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 95] [Article Influence: 4.9] [Reference Citation Analysis]
165 Watanabe S, Ishihara H, Takagi T, Kondo T, Ishiyama R, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Ishida H, Tanabe K. Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus. Jpn J Clin Oncol 2021;51:819-25. [PMID: 33558883 DOI: 10.1093/jjco/hyaa275] [Reference Citation Analysis]
166 Arai Y, Nonomura N, Nakai Y, Nishimura K, Oka D, Shiba M, Nakayama M, Takayama H, Mizutani Y, Miki T, Okuyama A. The Growth-Inhibitory Effects of Dexamethasone on Renal Cell Carcinoma In Vivo and In Vitro. Cancer Investigation 2009;26:35-40. [DOI: 10.1080/07357900701638418] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
167 Saito K, Kihara K. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 2011;8:659-66. [DOI: 10.1038/nrurol.2011.145] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 6.5] [Reference Citation Analysis]
168 Koo AS, Armstrong C, Bochner B, Shimabukuro T, Tso C, deKernion JB, Belldegrun A. Interleukin-6 and renal cell cancer: Production, regulation, and growth effects. Cancer Immunol Immunother 1992;35:97-105. [DOI: 10.1007/bf01741856] [Cited by in Crossref: 79] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
169 Böhm M, Ittenson A, Philipp C, Röhl F, Ansorge S, Allhoff E. COMPLEX PERIOPERATIVE IMMUNO-DYSFUNCTION IN PATIENTS WITH RENAL CELL CARCINOMA. Journal of Urology 2001;166:831-6. [DOI: 10.1016/s0022-5347(05)65846-6] [Cited by in Crossref: 8] [Article Influence: 0.4] [Reference Citation Analysis]
170 Mulé JJ, McIntosh JK, Jablons DM, Rosenberg SA. Antitumor activity of recombinant interleukin 6 in mice. J Exp Med. 1990;171:629-636. [PMID: 2307930 DOI: 10.1084/jem.171.3.629] [Cited by in Crossref: 163] [Cited by in F6Publishing: 149] [Article Influence: 5.3] [Reference Citation Analysis]
171 Shirota K, LeDuy L, Yuan SY, Jothy S. Interleukin-6 and its receptor are expressed in human intestinal epithelial cells. Virchows Arch B Cell Pathol Incl Mol Pathol 1990;58:303-8. [PMID: 1970694 DOI: 10.1007/BF02890085] [Cited by in Crossref: 99] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
172 Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199-207. [DOI: 10.1002/(sici)1097-0045(19990215)38:3<199::aid-pros4>3.0.co;2-h] [Cited by in Crossref: 153] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
173 Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H, Kobayashi T, Kawakami S, Kihara K. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 2008;101:978-981. [PMID: 18190628 DOI: 10.1111/j.1464-410x.2007.07408.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
174 Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Namba Y, Kishikawa H, Takahara S, Ichikawa Y. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels. Prostate Cancer Prostatic Dis 2008;11:258-63. [PMID: 17876341 DOI: 10.1038/sj.pcan.4501006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
175 Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 2007;99:77-80. [DOI: 10.1111/j.1464-410x.2006.06497.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
176 Spiotto MT, Chung TD. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 2000;42:88-98. [DOI: 10.1002/(sici)1097-0045(20000201)42:2<88::aid-pros2>3.0.co;2-p] [Cited by in Crossref: 101] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
177 Liu Q, Zhao S, Su PF, Yu S. Gene and isoform expression signatures associated with tumor stage in kidney renal clear cell carcinoma. BMC Syst Biol 2013;7 Suppl 5:S7. [PMID: 24564989 DOI: 10.1186/1752-0509-7-S5-S7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
178 Lu C, Vickers MF, Kerbel RS. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA. 1992;89:9215-9219. [PMID: 1409627 DOI: /10.1073/pnas.89.19.9215] [Reference Citation Analysis]
179 Otto F, Mackensen A, Mertelsmann R, Engelhardt R. Complete response of metastatic renal cell carcinoma to low-dose interferon-? treatment. Cancer Immunol Immunother 1995;40:115-8. [DOI: 10.1007/bf01520293] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
180 Omae K, Kondo T, Tanabe K. High preoperative C-reactive protein values predict poor survival in patients on chronic hemodialysis undergoing nephrectomy for renal cancer. Urologic Oncology: Seminars and Original Investigations 2015;33:67.e9-67.e13. [DOI: 10.1016/j.urolonc.2014.07.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
181 Yamabuki T, Ohara M, Kato M, Kimura N, Shirosaki T, Okamura K, Fujiwara A, Takahashi R, Komuro K, Iwashiro N, Hirano S. Cervical Castleman's disease mimicking lymph node metastasis of esophageal carcinoma. World J Gastrointest Oncol 2017;9:397-401. [PMID: 28979723 DOI: 10.4251/wjgo.v9.i9.397] [Reference Citation Analysis]
182 Cai W, Chen QY, Dang LH, Luesch H. Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors. ACS Med Chem Lett 2017;8:1007-12. [PMID: 29057042 DOI: 10.1021/acsmedchemlett.7b00192] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
183 Lin Y, Chang Z, Liao Y, Chou M, Tang C. IL-6 promotes ICAM-1 expression and cell motility in human osteosarcoma. Cancer Letters 2013;328:135-43. [DOI: 10.1016/j.canlet.2012.08.029] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
184 Miki HIC. Profile of Circulating Levels of Interleukin-1 Receptor Antagonist and Interleukin-6 in Colorectal Cancer Patients. Scandinavian Journal of Gastroenterology 2009;34:1139-43. [DOI: 10.1080/003655299750024959] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
185 Corcoran NM, Costello AJ. Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 2003;91:545-53. [PMID: 12656913 DOI: 10.1046/j.1464-410x.2003.04025.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
186 Esuvaranathan K, Alexandroff A, Mcintyre M, Jackson A, Prescott S, Chisholm G, James K. Interleukin-6 Production by Bladder Tumors is Upregulated by BCG Immunotherapy. Journal of Urology 1995;154:572-5. [DOI: 10.1016/s0022-5347(01)67113-1] [Cited by in Crossref: 46] [Article Influence: 1.8] [Reference Citation Analysis]
187 Gandour-edwards R, Kapadia SB, Gumerlock PH, Barnes L. Immunolocalization of interleukin-6 in salivary gland tumors. Human Pathology 1995;26:501-3. [DOI: 10.1016/0046-8177(95)90245-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
188 Steffens S, Köhler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G, Schrader M, Kuczyk MA, Schrader AJ. Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer 2012;12:399. [PMID: 22958305 DOI: 10.1186/1471-2407-12-399] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.8] [Reference Citation Analysis]
189 Songür N, Kuru B, Kalkan F, Özdilekcan Ç, Çakmak H, Hızel N. Serum Interleukin-6 Levels Correlate with Malnutrition and Survival in Patients with Advanced Non-Small Cell Lung Cancer. Tumori 2004;90:196-200. [DOI: 10.1177/030089160409000207] [Cited by in Crossref: 53] [Cited by in F6Publishing: 25] [Article Influence: 17.7] [Reference Citation Analysis]
190 Favaro D, Santarosa M, Quaia M, Galligioni E. Interleukin-6 and soluble intercellular adhesion molecule-1 in renal cancer patients and cultured renal cancer cells. Urol Oncol 1997;3:51-8. [PMID: 21227060 DOI: 10.1016/s1078-1439(97)00036-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
191 Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, Ogura T. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer. 1995;71:1095-1098. [PMID: 7734307 DOI: 10.1038/bjc.1995.212] [Cited by in Crossref: 122] [Cited by in F6Publishing: 117] [Article Influence: 4.7] [Reference Citation Analysis]
192 Ueno S, Saito S, Wada T, Yamaguchi K, Satoh M, Arai Y, Miyagi T. Plasma Membrane-associated Sialidase Is Up-regulated in Renal Cell Carcinoma and Promotes Interleukin-6-induced Apoptosis Suppression and Cell Motility. Journal of Biological Chemistry 2006;281:7756-64. [DOI: 10.1074/jbc.m509668200] [Cited by in Crossref: 92] [Cited by in F6Publishing: 30] [Article Influence: 6.1] [Reference Citation Analysis]
193 Ulane CM, Rodriguez JJ, Parisien JP, Horvath CM. STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. J Virol. 2003;77:6385-6393. [PMID: 12743296 DOI: 10.1128/jvi.77.11.6385-6393.2003] [Cited by in Crossref: 139] [Cited by in F6Publishing: 93] [Article Influence: 7.7] [Reference Citation Analysis]
194 Atretkhany KN, Drutskaya MS, Nedospasov SA, Grivennikov SI, Kuprash DV. Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. Pharmacol Ther 2016;168:98-112. [PMID: 27613100 DOI: 10.1016/j.pharmthera.2016.09.011] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 11.8] [Reference Citation Analysis]
195 Bookman MA, Berek JS. Biologic and Immunologic Therapy of Ovarian Cancer. Hematology/Oncology Clinics of North America 1992;6:941-65. [DOI: 10.1016/s0889-8588(18)30320-4] [Cited by in Crossref: 9] [Article Influence: 0.3] [Reference Citation Analysis]
196 Mitsuyama K, Sata M, Tanikawa K. Significance of interleukin-6 in patients with inflammatory bowel disease. Gastroenterol Jpn 1991;26:20-8. [PMID: 2007457 DOI: 10.1007/BF02779504] [Cited by in Crossref: 57] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
197 Babu A, Lachmann H, Pickett T, Boddana P, Ludeman L. Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature. CEN Case Rep 2014;3:68-74. [PMID: 28509249 DOI: 10.1007/s13730-013-0088-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
198 Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R, Massuger LF. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. Eur J Cancer. 2011;47:1883-1889. [PMID: 21514148 DOI: 10.1016/j.ejca.2011.03.026] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
199 Tartour E, Lee R, Fridman W. Anti-cytokines: promising tools for diagnosis and immunotherapy. Biomedicine & Pharmacotherapy 1994;48:417-24. [DOI: 10.1016/0753-3322(94)90002-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
200 Tartour E, Fridman WH. Cytokines and cancer. Int Rev Immunol. 1998;16:683-704. [PMID: 9646182 DOI: 10.3109/08830189809043014] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 1.4] [Reference Citation Analysis]
201 Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis & Rheumatism 1992;35:982-3. [DOI: 10.1002/art.1780350824] [Cited by in Crossref: 101] [Cited by in F6Publishing: 90] [Article Influence: 3.5] [Reference Citation Analysis]
202 Romero R, Sepulveda W, Kenney JS, Archer LE, Allison AC, Sehgal PB. Interleukin 6 determination in the detection of microbial invasion of the amniotic cavity. Ciba Found Symp 1992;167:205-20; discussion 220-3. [PMID: 1425014 DOI: 10.1002/9780470514269.ch13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 54] [Article Influence: 0.1] [Reference Citation Analysis]
203 Miki S, Matsumoto A, Nakamura Y, Itakura H, Kodama T, Yamamoto M, Miki Y. Expression of scavenger receptors on renal cell carcinoma cells in vitro. Biochemical and Biophysical Research Communications 1992;189:1323-8. [DOI: 10.1016/0006-291x(92)90218-a] [Cited by in Crossref: 8] [Article Influence: 0.3] [Reference Citation Analysis]
204 Li YY, Chang JW, Hsieh LL, Yeh KY. Neutralization of interleukin (IL)-10 released by monocytes/macrophages enhances the up-regulatory effect of monocyte/macrophage-derived IL-6 on expressions of IL-6 and MUC1, and migration in HT-29 colon cancer cells. Cell Immunol. 2010;265:164-171. [PMID: 20851386 DOI: 10.1016/j.cellimm.2010.07.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
205 Lavie O, Comerci G, Daras V, Bolger BS, Lopes A, Monaghan JM. Thrombocytosis in Women with Vulvar Carcinoma. Gynecologic Oncology 1999;72:82-6. [DOI: 10.1006/gyno.1998.5225] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
206 Schweinitz DV, Hadam MR, Welte K, Mildenberger H, Pietsch T. Production of interleukin-1β and interleukin-6 in hepatoblastoma. Int J Cancer 1993;53:728-34. [DOI: 10.1002/ijc.2910530504] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
207 Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate 2000;42:239-42. [DOI: 10.1002/(sici)1097-0045(20000215)42:3<239::aid-pros10>3.0.co;2-g] [Cited by in Crossref: 177] [Cited by in F6Publishing: 85] [Article Influence: 8.4] [Reference Citation Analysis]
208 Burger RA, Grosen EA, Ioli GR, Van Eden ME, Park M, Berman ML, Manetta A, Disaia PJ, Granger GA, Gatanaga T. Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovarian carcinoma. J Interferon Cytokine Res 1995;15:255-60. [PMID: 7584672 DOI: 10.1089/jir.1995.15.255] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
209 Flørenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene. 1999;18:1023-1032. [PMID: 10023678 DOI: 10.1038/sj.onc.1202382] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 2.5] [Reference Citation Analysis]
210 Lee S, Ra J, Song J, Gwak C, Kwon H, Yim S, Hong S, Kim J, Lee K, Cho J, Park YS, Park C, Ahn H. Extracts from Citrus unshiu promote immune-mediated inhibition of tumor growth in a murine renal cell carcinoma model. Journal of Ethnopharmacology 2011;133:973-9. [DOI: 10.1016/j.jep.2010.07.018] [Cited by in Crossref: 52] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
211 van Spronsen DJ, de Weijer KJM, Mulders PFA, De Mulder PHM. Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anti-Cancer Drugs 2005;16:709-17. [DOI: 10.1097/01.cad.0000167901.58877.a3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
212 Malejczyk J, Malejczyk M, Urbanski A, Köck A, Jablonska S, Orth G, Luger TA. Constitutive release of IL6 by human papillomavirus type 16 (HPV16)-harboring keratinocytes: A mechanism augmenting the NK-cell-mediated lysis of HPV-bearing neoplastic cells. Cellular Immunology 1991;136:155-64. [DOI: 10.1016/0008-8749(91)90390-w] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
213 Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol. 2002;168:762-765. [PMID: 12131365 DOI: 10.1097/00005392-200208000-00095] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
214 Lahm H, Petral-Malec D, Yilmaz-Ceyhan A, Fischer JR, Lorenzoni M, Givel JC, Odartchenko N. Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor beta 1. Eur J Cancer 1992;28A:1894-9. [PMID: 1389533 DOI: 10.1016/0959-8049(92)90031-v] [Cited by in Crossref: 35] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
215 Rosztoczy I, Content J. The Effects of Various Cytokines on Interleukin-6 and Interferon-α Synthesis in Human Peripheral Blood Mononuclear Cells. Journal of Interferon Research 1990;10:637-45. [DOI: 10.1089/jir.1990.10.637] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
216 Wang LS, Chow KC, Wu CW. Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate. Br J Cancer 1999;80:1617-22. [PMID: 10408408 DOI: 10.1038/sj.bjc.6690571] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
217 Paule B, Clerc D, Rudant C, Coulombel C, Bonhomme-faivre L, Quillard J, Bisson M. Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma. Human Pathology 1998;29:421-4. [DOI: 10.1016/s0046-8177(98)90128-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
218 Yoshida O, Habuchi T, Ogawa O. Recent advances in the molecular genetics of urogenital tumors. Int J Urol 1994;1:1-16. [PMID: 7627831 DOI: 10.1111/j.1442-2042.1994.tb00001.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
219 Matsuda T, Hirano T. Interleukin 6 (IL-6). Biotherapy 1990;2:363-73. [DOI: 10.1007/bf02170085] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
220 Prommer E. Prostate cancer and liver dysfunction: a case of cytokine dysregulation. J Pain Symptom Manage 2007;34:225-6. [PMID: 17583470 DOI: 10.1016/j.jpainsymman.2007.05.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
221 Mallardo M, Giordano V, Dragonetti E, Scala G, Quinto I. DNA damaging agents increase the stability of interleukin-1 alpha, interleukin-1 beta, and interleukin-6 transcripts and the production of the relative proteins. Journal of Biological Chemistry 1994;269:14899-904. [DOI: 10.1016/s0021-9258(17)36550-x] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
222 Fukuda H, Takagi T, Kondo T, Yoshida K, Shimizu S, Nagashima Y, Tanabe K. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy. Int J Clin Oncol 2018;23:539-46. [DOI: 10.1007/s10147-017-1221-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
223 Dunlop RJ, Campbell CW. Cytokines and Advanced Cancer. Journal of Pain and Symptom Management 2000;20:214-32. [DOI: 10.1016/s0885-3924(00)00199-8] [Cited by in Crossref: 91] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
224 Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999;85:2526-31. [DOI: 10.1002/(sici)1097-0142(19990615)85:12<2526::aid-cncr6>3.0.co;2-3] [Cited by in Crossref: 108] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
225 Alsaffar RM, Ali S, Rashid S, Rashid SM, Majid S, Rehman MU. Immunomodulation: An immune regulatory mechanism in carcinoma therapeutics. Int Immunopharmacol 2021;99:107984. [PMID: 34303999 DOI: 10.1016/j.intimp.2021.107984] [Reference Citation Analysis]
226 Schmitter D, Lauber B, Fagg B, Stahel RA. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: Interleukin-6 production as a common feature. Int J Cancer 1992;51:296-301. [DOI: 10.1002/ijc.2910510220] [Cited by in Crossref: 95] [Cited by in F6Publishing: 93] [Article Influence: 3.3] [Reference Citation Analysis]
227 Yang W, Huang J, Wu H, Wang Y, Du Z, Ling Y, Wang W, Wu Q, Gao W. Molecular mechanisms of cancer cachexia‑induced muscle atrophy (Review). Mol Med Rep 2020;22:4967-80. [PMID: 33174001 DOI: 10.3892/mmr.2020.11608] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
228 Tartour E, Pannetier C, Mathiot C, Teillaud J, Sautès C, Kourilsky P, Fridman W. Prognostic value of cytokine and soluble Fcγ receptor assays in oncology. Immunology Letters 1995;44:145-8. [DOI: 10.1016/0165-2478(94)00206-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
229 Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S, Kihara K. Impact of C-Reactive Protein Kinetics on Survival of Patients with Metastatic Renal Cell Carcinoma. European Urology 2009;55:1145-54. [DOI: 10.1016/j.eururo.2008.10.012] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 7.3] [Reference Citation Analysis]
230 Knoefel B, Nuske K, Steiner T, Junker K, Kosmehl H, Rebstock K, Reinhold D, Junker U. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation. J Interferon Cytokine Res 1997;17:95-102. [PMID: 9058315 DOI: 10.1089/jir.1997.17.95] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 2.0] [Reference Citation Analysis]
231 Zelvyte I, Lindgren S, Janciauskiene S. Multiple effects of alpha1-antitrypsin on breast carcinoma MDA-MB 468 cell growth and invasiveness. Eur J Cancer Prev. 2003;12:117-124. [PMID: 12671535 DOI: 10.1097/00008469-200304000-00005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
232 Ershler WB. Interleukin-6: A Cytokine for Gerontolgists. Journal of the American Geriatrics Society 1993;41:176-81. [DOI: 10.1111/j.1532-5415.1993.tb02054.x] [Cited by in Crossref: 305] [Cited by in F6Publishing: 258] [Article Influence: 50.8] [Reference Citation Analysis]
233 Virtanen I, Lehto VP. Progression of malignancy in clear cell renal cell carcinomas. Scand J Surg 2004;93:112-7. [PMID: 15285562 DOI: 10.1177/145749690409300205] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
234 Thiounn N, Pages F, Flam T, Tartour E, Mosseri V, Zerbib M, Beuzeboc P, Deneux L, Fridman WH, Debré B. IL-6 is a survival prognostic factor in renal cell carcinoma. Immunology Letters 1997;58:121-4. [DOI: 10.1016/s0165-2478(97)00036-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
235 Möbus VJ, Moll R, Gerharz CD, Kieback DG, Merk O, Runnebaum IB, Linner S, Dreher L, Grill H, Kreienberg R. Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin. Int J Cancer 1998;77:415-23. [DOI: 10.1002/(sici)1097-0215(19980729)77:3<415::aid-ijc18>3.0.co;2-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
236 Esuvaranathan K, Alexandroff AB, McIntyre M, Jackson AM, Prescott S, Chisholm GD, James K. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol 1995;154:572-5. [PMID: 7609139 DOI: 10.1097/00005392-199508000-00072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 0.1] [Reference Citation Analysis]
237 Gogusev J, Augusti M, Chrétien Y, Droz D. Interleukin-6 and TNF alpha production in human renal cell carcinoma. Kidney Int 1993;44:585-92. [PMID: 8231032 DOI: 10.1038/ki.1993.285] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
238 Yamaguchi T, Yamamoto Y, Yokota S, Nakagawa M, Ito M, Ogura T. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol. 1998;28:740-744. [PMID: 9879291 DOI: 10.1093/jjco/28.12.740] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 2.2] [Reference Citation Analysis]
239 Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Letters 2000;151:31-8. [DOI: 10.1016/s0304-3835(99)00401-2] [Cited by in Crossref: 100] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
240 Moriyama K, Williams PJ, Niewolna M, Dallas MR, Uehara Y, Mundy GR, Yoneda T. Herbimycin A, a tyrosine kinase inhibitor, impairs hypercalcemia associated with a human squamous cancer producing interleukin-6 in nude mice. J Bone Miner Res 1996;11:905-11. [DOI: 10.1002/jbmr.5650110706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
241 Kabir S, Grant C, Daar A. Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Letters 1995;95:207-12. [DOI: 10.1016/0304-3835(95)03895-4] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 2.0] [Reference Citation Analysis]
242 Gallo O, Bani D, Giudizi MG, Biagiotti R, Almerigogna F, Toccafondi G, Fini-Storchi O, Romagnani S. Spontaneous in vitro differentiation of a myoepithelial cell line (PA 16/23) from a pleomorphic adenoma of the parotid gland is associated with reduced production of the autocrine growth factor interleukin 6. Br J Cancer 1994;69:1065-71. [PMID: 8198972 DOI: 10.1038/bjc.1994.209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
243 Shaarawy M, Darwish NA. Serum Cytokines in Gestational Trophoblastic Diseases. Acta Oncologica 2009;34:177-82. [DOI: 10.3109/02841869509093953] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
244 Bertschi D, McKinnon BD, Evers J, Bersinger NA, Mueller MD. Enhanced inflammatory activity of endometriotic lesions from the rectovaginal septum. Mediators Inflamm 2013;2013:450950. [PMID: 24453419 DOI: 10.1155/2013/450950] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
245 Eggers H, Seidel C, Schrader AJ, Lehmann R, Wegener G, Kuczyk MA, Steffens S. Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder. Med Oncol 2013;30:705. [PMID: 24005810 DOI: 10.1007/s12032-013-0705-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
246 Kurebayashi J, Yamamoto S, Otsuki T, Sonoo H. Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. Br J Cancer 1999;79:631-6. [PMID: 10027341 DOI: 10.1038/sj.bjc.6690099] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
247 Oya M, Takayanagi A, Horiguchi A, Mizuno R, Ohtsubo M, Marumo K, Shimizu N, Murai M. Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis. 2003;24:377-384. [PMID: 12663495 DOI: 10.1093/carcin/24.3.377] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 4.6] [Reference Citation Analysis]
248 Johnson C, Han Y, Hughart N, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer 2012;1:58-70. [PMID: 22724089 DOI: 10.3978/j.issn.2224-4778.2011.11.02] [Cited by in F6Publishing: 60] [Reference Citation Analysis]
249 Bauer J, Herrmann F. Interleukin-6 in clinical medicine. Ann Hematol 1991;62:203-10. [DOI: 10.1007/bf01729833] [Cited by in Crossref: 91] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
250 Dougherty GJ, Dean Thacker J, Lavey RS, Belldegrun A, Mcbride WH. Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth in vivo. Cancer Immunol Immunother 1994;38:339-45. [DOI: 10.1007/bf01525513] [Cited by in Crossref: 20] [Article Influence: 0.7] [Reference Citation Analysis]
251 Algarra MA, Fita MJJ, Sandiego S, Aguilar HA, Álvarez P, Quispe M, Salvador A, Egido A, Lavernia J, Machado I, Rubio-Briones J, Climent MÁ. Advanced systemic amyloidosis secondary to metastatic renal cell carcinoma. Ecancermedicalscience 2020;14:1156. [PMID: 33574901 DOI: 10.3332/ecancer.2020.1156] [Reference Citation Analysis]
252 Seguchi T, Yokokawa K, Sugao H, Nakano E, Sonoda T, Okuyama A. Interleukin-6 activity in urine and serum in patients with bladder carcinoma. J Urol 1992;148:791-4. [PMID: 1512827 DOI: 10.1016/s0022-5347(17)36721-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
253 Yigit R, Massuger LF, Zusterzeel PL, Pots J, Figdor CG, Torensma R. Cytokine profiles in cyst fluids from ovarian tumors reflect immunosuppressive state of the tumor. Int J Gynecol Cancer. 2011;21:1241-1247. [PMID: 21946293 DOI: 10.1097/igc.0b013e3182289ab1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
254 Li M, Gunter ME, Fukagawa NK. Differential activation of the inflammasome in THP-1 cells exposed to chrysotile asbestos and Libby "six-mix" amphiboles and subsequent activation of BEAS-2B cells. Cytokine 2012;60:718-30. [PMID: 23017228 DOI: 10.1016/j.cyto.2012.08.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
255 Siegsmund MJ, Yamazaki H, Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol 1994;151:1396-9. [PMID: 7512667 DOI: 10.1016/s0022-5347(17)35267-9] [Cited by in Crossref: 61] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
256 Asbagh LA, Uzunoglu S, Cal C. Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines. Int braz j urol 2008;34:355-64. [DOI: 10.1590/s1677-55382008000300013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
257 Ward BC, Kavalukas S, Brugnano J, Barbul A, Panitch A. Peptide inhibitors of MK2 show promise for inhibition of abdominal adhesions. J Surg Res 2011;169:e27-36. [PMID: 21492875 DOI: 10.1016/j.jss.2011.01.043] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
258 Ali S, Yin-goen Q, Johnson TV, Han W, Johnson NA, Harris WB, Marshall FF, Young AN, Master VA, Osunkoya AO. Expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma: correlation with pathological parameters in 110 patients. Tumor Biol 2011;32:375-80. [DOI: 10.1007/s13277-010-0130-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
259 Gockel I, Dirksen K, Messow CM, Junginger T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol. 2006;12:3746-3750. [PMID: 16773693 DOI: 10.3748/wjg.v12.i23.3746] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 65] [Article Influence: 4.7] [Reference Citation Analysis]
260 Scholz W. Interleukin 6 in diseases: Cause or cure? Immunopharmacology 1996;31:131-50. [DOI: 10.1016/0162-3109(95)00040-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
261 Scambia G, Testa U, Panici PB, Martucci R, Foti E, Petrini M, Amoroso M, Masciullo V, Peschle C, Mancuso S. Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 1994;57:318-23. [PMID: 8168990 DOI: 10.1002/ijc.2910570305] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 2.4] [Reference Citation Analysis]
262 Poppenborg H, Knüpfer MM, Galla H, Alexander Wolff JE. IN VITRO MODULATION OF CISPLATIN RESISTANCE BY CYTOKINES. Cytokine 1999;11:689-95. [DOI: 10.1006/cyto.1998.0473] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
263 Tachibana M, Miyakawa A, Nakashima J, Murai M, Nakamura K, Kubo A, Hata JI. Constitutive production of multiple cytokines and a human chorionic gonadotrophin beta-subunit by a human bladder cancer cell line (KU-19-19): possible demonstration of totipotential differentiation. Br J Cancer 1997;76:163-74. [PMID: 9231915 DOI: 10.1038/bjc.1997.358] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
264 Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC Jr. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. Am J Obstet Gynecol 1992;166:997-1007. [PMID: 1550178 DOI: 10.1016/0002-9378(92)91379-o] [Cited by in Crossref: 72] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
265 Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002;4 Suppl 3:S233-42. [PMID: 12110143 DOI: 10.1186/ar565] [Cited by in Crossref: 321] [Cited by in F6Publishing: 292] [Article Influence: 16.9] [Reference Citation Analysis]
266 Inoue Y, Miki C, Watanabe H, Ojima E, Kusunoki M. Genomic instability and tissue expression of angiogenic growth factors in sporadic colorectal cancer. Surgery 2006;139:305-11. [PMID: 16546493 DOI: 10.1016/j.surg.2005.08.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
267 Tefferi A, Ho TC, Ahmann GJ, Katzmann JA, Greipp PR. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med 1994;97:374-8. [PMID: 7942941 DOI: 10.1016/0002-9343(94)90306-9] [Cited by in Crossref: 80] [Cited by in F6Publishing: 57] [Article Influence: 3.0] [Reference Citation Analysis]
268 Mcmillan DC, Wotherspoon HA, Fearon KC, Sturgeon C, Cooke TG, Mcardle CS. A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. The American Journal of Surgery 1995;170:319-22. [DOI: 10.1016/s0002-9610(99)80296-7] [Cited by in Crossref: 106] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
269 Kaminski JM, Shinohara E, Summers JB, Niermann KJ, Morimoto A, Brousal J. The controversial abscopal effect. Cancer Treatment Reviews 2005;31:159-72. [DOI: 10.1016/j.ctrv.2005.03.004] [Cited by in Crossref: 147] [Cited by in F6Publishing: 130] [Article Influence: 9.2] [Reference Citation Analysis]
270 Bian ZY, Fan QM, Li G, Xu WT, Tang TT. Human mesenchymal stem cells promote growth of osteosarcoma: involvement of interleukin-6 in the interaction between human mesenchymal stem cells and Saos-2. Cancer Sci. 2010;101:2554-2560. [PMID: 20874851 DOI: 10.1111/j.1349-7006.2010.01731.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
271 Kinoshita Y, Kono T, Yasumoto R, Kishimoto T, Wang CY, Haas GP, Nishisaka N. Antitumor Effect on Murine Renal Cell Carcinoma by Autologous Tumor Vaccines Genetically Modified with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-6 Cells: . Journal of Immunotherapy 2001;24:205-11. [DOI: 10.1097/00002371-200105000-00003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
272 Fontaine V, Brakenhoff J, De Wit L, Arcone R, Ciliberto G, Content J. Internal deletions in human interleukin-6: structure-function analysis. Gene 1991;104:227-34. [PMID: 1916293 DOI: 10.1016/0378-1119(91)90254-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
273 Revel M. Growth regulatory functions of IL6 and antitumour effects. Research in Immunology 1992;143:769-73. [DOI: 10.1016/0923-2494(92)80021-c] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
274 Araki K, Igarashi T, Tobe T, Mizoguchi K, Suzuki H, Furuya Y, Ichikawa T, Nakatsu H, Ito H. Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy. Urology 2006;68:1178-82. [DOI: 10.1016/j.urology.2006.08.1071] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
275 Knüpfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 2007;102:129-35. [PMID: 16927176 DOI: 10.1007/s10549-006-9328-3] [Cited by in Crossref: 249] [Cited by in F6Publishing: 232] [Article Influence: 16.6] [Reference Citation Analysis]